Cytovia, Cellectis Expand Collaboration On Gene-Edited Cancer Platform In China

  • Cytovia Therapeutics Inc and Cellectis SA CLLS have expanded their collaboration of TALEN gene-edited iPSC-derived NK and CAR-NK cells.
  • The expanded agreement will include a new CAR target and development in China by Cytovia's joint venture entity, CytoLynx Therapeutics.
  • The amended financial terms include an equity stake of $20 million in Cytovia stock and up to $805 million in milestones and single-digit sales-based royalty payments.
  • Cytovia will develop iNK products leveraging Cellectis' TALEN to perform gene-editing to minimize the risk of off-target effects and unlock the full potential of NK cells as the first line of defense against cancer. 
  • Cytovia is responsible for the differentiation and expansion of the gene-edited iPSC master cell bank into NK cells and is conducting the preclinical evaluation, clinical development, and commercialization. 
  • Related Link: Cellectis Unveils Four Additional Preclinical Candidates For Solid Tumors.
  • Price Action: CLLS shares closed at $9.1 on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsSmall CapGeneralBriefscancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!